Eton Pharmaceuticals (ETON) Non-Current Assets (2017 - 2026)

Eton Pharmaceuticals has disclosed Non-Current Assets across 10 years of filings, most recently posting $47.2 million for Q2 2026.

• In Q2 2026, Non-Current Assets rose 42.05% year-over-year to $47.2 million; the TTM figure through Jun 2026 stood at $144.5 million (up 33.17% YoY), while the FY2025 annual figure was $31.5 million, down 10.17% from the prior year.
• Non-Current Assets came in at $47.2 million for Q2 2026 at Eton Pharmaceuticals, up from $31.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $47.2 million in Q2 2026 to a low of $3.3 million in Q2 2022.
• Average Non-Current Assets over 5 years is $15.8 million, with a median of $6.1 million recorded in 2024.
• Year-over-year, Non-Current Assets dropped 14.33% in 2023 and surged 616.22% in 2024.
• Over 5 years, Non-Current Assets stood at $5.0 million in 2022, then slipped by 2.49% to $4.9 million in 2023, then surged by 616.22% to $35.1 million in 2024, then fell by 10.17% to $31.5 million in 2025, then soared by 49.71% to $47.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $47.2 million in Q2 2026, $31.5 million in Q4 2025, and $32.5 million in Q3 2025.